Product Description
Diphenhydramine is used to relieve red, irritated, itchy, watery eyes; sneezing; and runny nose caused by hay fever, allergies, or the common cold. Diphenhydramine is also used to relieve cough caused by minor throat or airway irritation.
Mechanisms of Action: H1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Poland, United States
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Acute Urticaria|Multiple Sclerosis|Schizophrenia
Phase 2: Type 1 Diabetes
Phase 1: Healthy Volunteers|Insomnia|Pain Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PTG007DM1preTREG001 | P2 |
Unknown Status |
Type 1 Diabetes |
2032-10-31 |
|
| Ketamine in negative symptoms | P3 |
Active, not recruiting |
Schizophrenia |
2024-11-03 |
|
| YYKQ-202210 | P1 |
Not yet recruiting |
Insomnia |
2023-10-31 |
43% |
| SIBP-R002 | P1 |
Completed |
Unknown |
2023-01-09 |
21% |
| SIBP-R002 | P1 |
Completed |
Unknown |
2023-01-09 |
21% |